NASDAQ:DVAXDynavax Technologies Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dynavax Technologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $8.82 -0.17 (-1.89 %) (As of 08/6/2020 04:00 PM ET) Add Compare Share Today's Range$8.63Now: $8.82▼$9.1050-Day Range$6.01MA: $8.68▼$11.7052-Week Range$1.80Now: $8.82▼$12.44Volume2.76 million shsAverage Volume7.15 million shsMarket Capitalization$813.03 millionP/E RatioN/ADividend YieldN/ABeta1.12 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; and a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is headquartered in Emeryville, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDynavax Technologies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.00, Dynavax Technologies has a potential upside of 81.4% from its current price of $8.82.Amount of Analyst CoverageDynavax Technologies has only been the subject of 4 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesDynavax Technologies has received 433 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDynavax Technologies has received 426 “underperform” votes. (Add your “underperform” vote.)Community SentimentDynavax Technologies has received 50.41% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Vote “Outperform” if you believe DVAX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DVAX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDynavax Technologies does not currently pay a dividend.Dividend GrowthDynavax Technologies does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dynavax Technologies insiders have bought 645.25% more of their company's stock than they have sold. Specifically, they have bought $4,840,000.00 in company stock and sold $649,450.00 in company stock.Percentage Held by InsidersOnly 13.33% of the stock of Dynavax Technologies is held by insiders.Percentage Held by Institutions71.10% of the stock of Dynavax Technologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dynavax Technologies are expected to grow in the coming year, from ($0.95) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dynavax Technologies is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dynavax Technologies is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDynavax Technologies has a P/B Ratio of 88.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.13 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:DVAX Previous Symbol CUSIP26815810 CIK1029142 Webwww.dynavax.com Phone510-848-5100Debt Debt-to-Equity Ratio18.31 Current Ratio6.63 Quick Ratio4.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$35.22 million Price / Sales23.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book88.20Profitability EPS (Most Recent Fiscal Year)($1.87) Net Income$-152,600,000.00 Net Margins-310.97% Return on Equity-722.75% Return on Assets-45.63%Miscellaneous Employees231 Outstanding Shares92,180,000Market Cap$813.03 million Next Earnings Date8/6/2020 (Confirmed) OptionableOptionable $8.82 -0.17 (-1.89 %) (As of 08/6/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DVAX News and Ratings via Email Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Dynavax Technologies (NASDAQ:DVAX) Frequently Asked Questions How has Dynavax Technologies' stock been impacted by COVID-19 (Coronavirus)? Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DVAX shares have increased by 186.6% and is now trading at $8.80. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Dynavax Technologies? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dynavax Technologies. When is Dynavax Technologies' next earnings date? Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Dynavax Technologies. How were Dynavax Technologies' earnings last quarter? Dynavax Technologies Co. (NASDAQ:DVAX) posted its earnings results on Wednesday, March, 11th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by $0.11. The biopharmaceutical company earned $10.57 million during the quarter, compared to analyst estimates of $11.92 million. Dynavax Technologies had a negative return on equity of 722.75% and a negative net margin of 310.97%. View Dynavax Technologies' earnings history. What price target have analysts set for DVAX? 4 analysts have issued 12 month price objectives for Dynavax Technologies' stock. Their forecasts range from $14.00 to $20.00. On average, they expect Dynavax Technologies' stock price to reach $16.00 in the next year. This suggests a possible upside of 81.8% from the stock's current price. View analysts' price targets for Dynavax Technologies. Has Dynavax Technologies been receiving favorable news coverage? News coverage about DVAX stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Dynavax Technologies earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Dynavax Technologies. Who are some of Dynavax Technologies' key competitors? Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Dynavax Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Micron Technology (MU), Array Biopharma (ARRY), Gilead Sciences (GILD) and Exelixis (EXEL). Who are Dynavax Technologies' key executives? Dynavax Technologies' management team includes the following people: Mr. Ryan Spencer, CEO & Director (Age 42, Pay $545.59k)Mr. David F. Novack, Pres & COO (Age 58, Pay $697.27k)Mr. Michael S. Ostrach, CFO, Chief Bus. Officer & Sr. VP (Age 68, Pay $662.54k)Dr. Robert Janssen, Chief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs (Age 66, Pay $666.13k)Mr. David Lee Johnson, VP & Chief Accounting Officer (Age 66) What is Dynavax Technologies' stock symbol? Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX." Who are Dynavax Technologies' major shareholders? Dynavax Technologies' stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (5.32%), Rhenman & Partners Asset Management AB (1.00%), Swiss National Bank (0.23%), DC Investments Management LLC (0.21%), Virtus ETF Advisers LLC (0.07%) and Cambridge Investment Research Advisors Inc. (0.05%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David Louis Johnson, Francis Cano, Michael S Ostrach, Robert Coffman and Robert Janssen. View institutional ownership trends for Dynavax Technologies. Which major investors are selling Dynavax Technologies stock? DVAX stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, UBS Group AG, and Gables Capital Management Inc.. View insider buying and selling activity for Dynavax Technologies. Which major investors are buying Dynavax Technologies stock? DVAX stock was purchased by a variety of institutional investors in the last quarter, including Chicago Capital LLC, DC Investments Management LLC, Virtus ETF Advisers LLC, Swiss National Bank, Mesirow Financial Investment Management Inc., Principal Financial Group Inc., Hancock Whitney Corp, and MERIAN GLOBAL INVESTORS UK Ltd. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano. View insider buying and selling activity for Dynavax Technologies. How do I buy shares of Dynavax Technologies? Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Dynavax Technologies' stock price today? One share of DVAX stock can currently be purchased for approximately $8.80. How big of a company is Dynavax Technologies? Dynavax Technologies has a market capitalization of $811.18 million and generates $35.22 million in revenue each year. The biopharmaceutical company earns $-152,600,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. Dynavax Technologies employs 231 workers across the globe. What is Dynavax Technologies' official website? The official website for Dynavax Technologies is www.dynavax.com. How can I contact Dynavax Technologies? Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected] This page was last updated on 8/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
